Literature DB >> 3153472

The cellular actions of vasopressin on corticotrophs of the anterior pituitary: resistance to glucocorticoid action.

L M Bilezikjian1, A L Blount, W W Vale.   

Abstract

The cellular actions of vasopressin (AVP) in the anterior pituitary were investigated. HPLC analysis of [3H]inositol-labeled cells indicated that AVP stimulated a rapid increase in inositol-1,4,5 trisphosphate (IP3), inositol-1,4 bisphosphate, and inositol-4 monophosphate levels. While CRF had no effect on basal IP3 levels, it blocked their stimulation by AVP. CRF-stimulated ACTH secretion and cAMP accumulation were potentiated by AVP. AFter dexamethasone (DEX) treatment (20 nM, 18 h), CRF-dependent ACTH secretion and cAMP accumulation were attenuated but AVP was still able to potentiate both of these actions of CRF suggesting that cellular actions of AVP may be resistant to DEX effects. Therefore, [3H]AVP binding was determined in control and DEX-treated cells. Pretreatment with DEX had no effect on either AVP receptor affinity or on the number of available binding sites. Consistently, stimulation of IP3 production by AVP in DEX-treated cells was comparable to that of control cells. Protein kinase C activators such as 12-O-tetradecanoyl-phorbol-13-acetate and dioctanoylglycerol were either near additive with CRF or also potentiated the action of CRF on ACTH secretion, respectively, even after DEX pretreatment. These results indicate that, in the anterior pituitary, distinct intracellular signaling pathways mediate the actions of CRF and AVP; cAMP mediates CRF actions and IP3/protein kinase C mediate the effects of AVP. Neuromodulation of ACTH secretion by dual effector mechanisms which exhibit a complex mode of interaction and only one of which is negatively influenced by glucocorticoids, provides these cells a mechanisms by which appropriate responses can be elicited under various physiological states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3153472     DOI: 10.1210/mend-1-7-451

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  9 in total

1.  Quantifying nonlinear interactions within the hypothalamo-pituitary-adrenal axis in the conscious horse.

Authors:  Daniel M Keenan; Sue Alexander; Clifford Irvine; Johannes D Veldhuis
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

Review 2.  Coexisting peptides in hypothalamic neuroendocrine systems: some functional implications.

Authors:  C A Bondy; M H Whitnall; L S Brady; H Gainer
Journal:  Cell Mol Neurobiol       Date:  1989-12       Impact factor: 5.046

3.  Changes in physiological and neuroendocrine properties during thermal adaptation of golden hamsters (Mesocricetus auratus).

Authors:  J Roth; G Merker; F Nürnberger; B Pauly; E Zeisberger
Journal:  J Comp Physiol B       Date:  1990       Impact factor: 2.200

Review 4.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

5.  Cortisol infusion in late-gestation hypothalamo-pituitary disconnected sheep fetus restores pituitary cell responsiveness to arginine vasopressin.

Authors:  Luke C Carey; Stephen B Tatter; James C Rose
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-11-25       Impact factor: 4.310

6.  Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors.

Authors:  Sharla F Young; Cristiana Griffante; Greti Aguilera
Journal:  Cell Mol Neurobiol       Date:  2007-02-21       Impact factor: 4.231

7.  Epigenetics of early child development.

Authors:  Chris Murgatroyd; Dietmar Spengler
Journal:  Front Psychiatry       Date:  2011-04-18       Impact factor: 4.157

8.  Stress responsiveness of the hypothalamic-pituitary-adrenal axis: age-related features of the vasopressinergic regulation.

Authors:  Nadezhda D Goncharova
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-12       Impact factor: 5.555

9.  Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment.

Authors:  A V Araya; P Rojas; R Fritsch; R Rojas; L Herrera; G Rojas; H Gatica; H Silva; J L Fiedler
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.